 |
12 Products |  |
51 Diseases | | 12 Products |
|
10 Trials |  |
1329 News |  |
| «12...567891011121314151617» |
- birinapant (IGM-9427) / IGM Biosciences
Enrollment change: 18F-CP18 Imaging Studies for Cancer Treatment With Birinapant (clinicaltrials.gov) - Jul 24, 2013
P2, N=0, Withdrawn, Sponsor: National Institutes of Health Clinical Center (CC)
N=10 --> 0
- | samatasvir (IDX719) / Merck (MSD)
New P1 trial: Drug-Drug Interaction Between IDX719, Simeprevir, TMC647055 and Ritonavir When Administered in Combination in Healthy Participants (MK-1894-007) (clinicaltrials.gov) - Jul 23, 2013
P1, N=32, Active, not recruiting, Sponsor: Idenix Pharmaceuticals
- || Adasuve (staccato loxapine) / AOP Orphan Pharma, Teva, Ferrer International, Galen, Medivir
Enrollment change: ADASUVE 2-dose Thorough QT/QTc Study (clinicaltrials.gov) - Jul 10, 2013
P1, N=60, Completed, Sponsor: Alexza Pharmaceuticals, Inc.
N=10 --> 0 N=48 --> 60
- ||| Adasuve (staccato loxapine) / AOP Orphan Pharma, Teva, Ferrer International, Galen, Medivir
Trial completion: ADASUVE 2-dose Thorough QT/QTc Study (clinicaltrials.gov) - Jul 10, 2013
P1, N=60, Completed, Sponsor: Alexza Pharmaceuticals, Inc.
N=48 --> 60 Recruiting --> Completed
- | Olysio (simeprevir) / J&J, Medivir
New P1 trial: A Study of Drug-drug Interaction Between Ritonavir and TMC435350 in Healthy Volunteers (clinicaltrials.gov) - Jul 1, 2013
P1, N=12, Completed, Sponsor: Tibotec Pharmaceuticals, Ireland
- | Adasuve (staccato loxapine) / AOP Orphan Pharma, Teva, Ferrer International, Galen, Medivir
New P1 trial: ADASUVE-Lorazepam Drug-Drug Interaction (clinicaltrials.gov) - Jun 12, 2013
P1, N=22, Completed, Sponsor: Alexza Pharmaceuticals, Inc.
- birinapant (IGM-9427) / IGM Biosciences
Enrollment change: Dose Escalation Safety Study of TL32711 in Adults With Refractory Solid Tumors or Lymphoma (clinicaltrials.gov) - May 20, 2013
P1, N=50, Completed, Sponsor: TetraLogic Pharmaceuticals
Recruiting --> Completed N=65 --> 50
- | birinapant (IGM-9427) / IGM Biosciences
Trial completion: Dose Escalation Safety Study of TL32711 in Adults With Refractory Solid Tumors or Lymphoma (clinicaltrials.gov) - May 20, 2013
P1, N=50, Completed, Sponsor: TetraLogic Pharmaceuticals
N=65 --> 50 Active, not recruiting --> Completed
- ||| Adasuve (staccato loxapine) / AOP Orphan Pharma, Teva, Ferrer International, Galen, Medivir
New P1 trial: ADASUVE 2-dose Thorough QT/QTc Study (clinicaltrials.gov) - May 13, 2013
P1, N=60, Completed, Sponsor: Alexza Pharmaceuticals, Inc.
- ||||| samatasvir (IDX719) / Merck (MSD)
New P2 trial: Samatasvir (IDX719) in Combinations With Simeprevir and/or TMC647055/Ritonavir With or Without Ribavirin for 12 Weeks in Participants With Chronic Hepatitis C Infection (MK-1894-005) (clinicaltrials.gov) - May 12, 2013
P2, N=143, Active, not recruiting, Sponsor: Idenix Pharmaceuticals
- |||||||||| Olysio (simeprevir) / J&J, Medivir
New P3 trial: A Study of TMC435 Plus Pegylated Interferon Alfa-2a and Ribavirin in Participants With Chronic HCV Infection (clinicaltrials.gov) - May 1, 2013
P3, N=225, Recruiting, Sponsor: Janssen-Cilag International NV
- | birinapant (IGM-9427) / IGM Biosciences
New P1/2 trial, Combination therapy: Birinapant With 5-azacitidine in MDS Subjects Who Are Na (clinicaltrials.gov) - Apr 8, 2013
P1/2, N=45, Recruiting, Sponsor: TetraLogic Pharmaceuticals
- samatasvir (IDX719) / Merck (MSD)
Enrollment closed: Study to Evaluate Drug-Drug Interaction Between IDX719 and Simeprevir in Healthy Participants (MK-1894-004) (clinicaltrials.gov) - Mar 25, 2013
P1, N=40, Active, not recruiting, Sponsor: Idenix Pharmaceuticals
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- | samatasvir (IDX719) / Merck (MSD)
New P1 trial: Study to Evaluate Drug-Drug Interaction Between IDX719 and Simeprevir in Healthy Participants (MK-1894-004) (clinicaltrials.gov) - Mar 17, 2013
P1, N=40, Active, not recruiting, Sponsor: Idenix Pharmaceuticals
- | Olysio (simeprevir) / J&J, Medivir
New P1 trial: A Pharmacokinetic Study to Assess the Effect of Food in Healthy Male Participants Receiving TMC435 (clinicaltrials.gov) - Feb 25, 2013
P1, N=24, Completed, Sponsor: Janssen Research & Development, LLC
- ||||||| Olysio (simeprevir) / J&J, Medivir
Trial completion: QUEST-2: An Efficacy, Safety, and Tolerability Study of TMC435 in Treatment-naive, Genotype 1 Hepatitis C-infected Participants (clinicaltrials.gov) - Feb 25, 2013
P3, N=393, Completed, Sponsor: Janssen R&D Ireland
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- ||||||| Olysio (simeprevir) / J&J, Medivir
Trial completion: PROMISE: An Efficacy, Safety and Tolerability Study of TMC435 in Genotype 1 Hepatitis C-infected Patients Who Relapsed After Previous Therapy (clinicaltrials.gov) - Feb 25, 2013
P3, N=394, Completed, Sponsor: Janssen R&D Ireland
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||||||| Olysio (simeprevir) / J&J, Medivir
Trial completion: QUEST-1: An Efficacy, Safety, and Tolerability Study of TMC435 in Treatment-naive, Genotype 1 Hepatitis C-infected Patients (clinicaltrials.gov) - Feb 20, 2013
P3, N=395, Completed, Sponsor: Janssen R&D Ireland
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Olysio (simeprevir) / J&J, Medivir, Incivek (telaprevir) / J&J, Vertex, Mitsubishi Tanabe
Enrollment closed, Combination therapy: TMC435HPC3001 - An Efficacy, Safety and Tolerability Study for TMC435 vs Telaprevir in Combination With PegINF?-2a and Ribavirin in Chronic Hepatitis C Patients Who Were Null or Partial Responders to Prior PegINF?-2a and Ribavirin Therapy (clinicaltrials.gov) - Feb 13, 2013
P3, N=766, Active, not recruiting, Sponsor: Janssen R&D Ireland
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- birinapant (IGM-9427) / IGM Biosciences
New P2 trial: 18F-CP18 Imaging Studies for Cancer Treatment With Birinapant (clinicaltrials.gov) - Jan 9, 2013
P2, N=0, Withdrawn, Sponsor: National Institutes of Health Clinical Center (CC)
- ||| Olysio (simeprevir) / J&J, Medivir
Enrollment closed: 3-year Follow-up Study in Patients Previously Treated With TMC435-Containing Regimen for the Treatment of Hepatitis C Virus Infection (clinicaltrials.gov) - Dec 23, 2012
P2b, N=249, Active, not recruiting, Sponsor: Janssen R&D Ireland
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- ||| Olysio (simeprevir) / J&J, Medivir
Trial initiation date, Combination therapy: A Study of TMC435 in Combination With PSI-7977 (GS7977) in Chronic Hepatitis C Genotype 1-Infected Prior Null Responders To Peginterferon/Ribavirin Therapy or HCV Treatment-Naive Patients (clinicaltrials.gov) - Dec 19, 2012
P2a, N=168, Completed, Sponsor: Janssen R&D Ireland
Recruiting --> Active, not recruiting Initiation date: Oct 2011 --> Jan 2012
- ||||||| Olysio (simeprevir) / J&J, Medivir
Trial completion: A Study of TMC435 in Participants With Genotype 1 Hepatitis C Virus (HCV) Infection (clinicaltrials.gov) - Dec 9, 2012
P3, N=79, Completed, Sponsor: Janssen Pharmaceutical K.K.
Initiation date: Oct 2011 --> Jan 2012 Active, not recruiting --> Completed
- Olysio (simeprevir) / J&J, Medivir
Trial completion: A Study to Assess the Absolute Bioavailability and Pharmacokinetics of Simeprevir (TMC435) Administered as Single Oral Doses of TMC435 and an Intravenous Microdose of [3H]-TMC435 in Healthy Male Patients (clinicaltrials.gov) - Dec 6, 2012
P1, N=6, Completed, Sponsor: Janssen R&D Ireland
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Olysio (simeprevir) / J&J, Medivir
Enrollment change: TMC435-TiDP16-C108 - A Study in Healthy Volunteers Investigating the Pharmacokinetic Interaction Between TMC435 and Digoxin and Between TMC435 and Rosuvastatin (clinicaltrials.gov) - Nov 28, 2012
P1, N=33, Completed, Sponsor: Tibotec Pharmaceuticals, Ireland
Active, not recruiting --> Completed N=16 --> 33
- ||| Daklinza (daclatasvir) / BMS
Enrollment closed, Combination therapy: Study of Daclatasvir (BMS-790052) and Simeprevir (TMC435) in Patients With Genotype 1 Chronic Hepatitis C Virus (clinicaltrials.gov) - Nov 25, 2012
P2, N=180, Active, not recruiting, Sponsor: Bristol-Myers Squibb
N=16 --> 33 Not yet recruiting --> Active, not recruiting
- Olysio (simeprevir) / J&J, Medivir
Enrollment change: A Pharmacokinetic Interaction Study Between TMC435, Atorvastatin and Simvastatin in Healthy Participants (clinicaltrials.gov) - Nov 19, 2012
P1, N=36, Completed, Sponsor: Janssen Research & Development, LLC
Not yet recruiting --> Active, not recruiting N=21 --> 36
- ||||||| Olysio (simeprevir) / J&J, Medivir
Trial completion: A Phase III Study of TMC435 in Treatment-naive, Genotype 1, Hepatitis C-infected Patients (clinicaltrials.gov) - Nov 18, 2012
P3, N=183, Completed, Sponsor: Janssen Pharmaceutical K.K.
N=21 --> 36 Active, not recruiting --> Completed
- |||||||||| Olysio (simeprevir) / J&J, Medivir
New P3 trial: A Study to Assess the Safety, Tolerability and Efficacy of TMC435 Along With Pegylated Interferon Alpha-2a (Pegasys) and Ribavirin (Copegus) Triple Therapy in Chronic Hepatitis C Genotype-1 Infected Patients Co-infected With Human Immunodeficiency Virus-Type 1 (clinicaltrials.gov) - Nov 13, 2012
P3, N=109, Active, not recruiting, Sponsor: Janssen Research & Development, LLC
- |||||||||| Olysio (simeprevir) / J&J, Medivir
New P3 trial: An Efficacy, Pharmacokinetics, Safety and Tolerability Study of TMC435 as Part of a Treatment Regimen for Hepatitis C-Infected Patients (clinicaltrials.gov) - Nov 12, 2012
P3, N=458, Active, not recruiting, Sponsor: Janssen R&D Ireland
- ||||| TMC647055 / J&J, Olysio (simeprevir) / J&J, Medivir
New P2a trial, Combination therapy: A Study to Evaluate the Safety, Tolerability, and Effectiveness of a 12-Week Combination Therapy of TMC647055 and TMC435 With and Without GSK23336805 With a Pharmacokinetic Enhancer With and Without Ribavirin in Patients Infected With Chronic Genotype 1 Hepatitis C Virus (clinicaltrials.gov) - Nov 7, 2012
P2a, N=86, Recruiting, Sponsor: Janssen R&D Ireland
- Olysio (simeprevir) / J&J, Medivir
New P1 trial: A Study to Assess the Absolute Bioavailability and Pharmacokinetics of Simeprevir (TMC435) Administered as Single Oral Doses of TMC435 and an Intravenous Microdose of [3H]-TMC435 in Healthy Male Patients (clinicaltrials.gov) - Oct 14, 2012
P1, N=6, Completed, Sponsor: Janssen R&D Ireland
- ||||||| Olysio (simeprevir) / J&J, Medivir
Trial completion: A Phase III Study of TMC435 in Genotype 1, Hepatitis C-infected Participants Who Failed to Respond to Previous IFN-based Therapy (clinicaltrials.gov) - Oct 7, 2012
P3, N=106, Completed, Sponsor: Janssen Pharmaceutical K.K.
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||| birinapant (IGM-9427) / IGM Biosciences
Enrollment closed, Combination therapy, Metastases: Dose Escalation, Combination Chemotherapy Safety Study of Birinapant (TL32711), in Subjects With Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - Sep 26, 2012
P1b/2a, N=200, Active, not recruiting, Sponsor: TetraLogic Pharmaceuticals
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- || Olysio (simeprevir) / J&J, Medivir
Trial completion: A Study of TMC435 in Genotype 1, Hepatitis C-infected Patients Who Relapsed After Previous Interferon (IFN)-Based Therapy (clinicaltrials.gov) - Sep 23, 2012
P3, N=49, Completed, Sponsor: Janssen Pharmaceutical K.K.
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- | Olysio (simeprevir) / J&J, Medivir
New P1 trial: A Pharmacokinetic Interaction Study Between TMC435, Atorvastatin and Simvastatin in Healthy Participants (clinicaltrials.gov) - Sep 19, 2012
P1, N=36, Completed, Sponsor: Janssen Research & Development, LLC
- birinapant (IGM-9427) / IGM Biosciences
New P2 trial, Metastases: Birinapant for Advanced Ovarian, Fallopian Tube, and Peritoneal Cancer (clinicaltrials.gov) - Sep 5, 2012
P2, N=11, Completed, Sponsor: National Cancer Institute (NCI)
- Olysio (simeprevir) / J&J, Medivir
Enrollment change: TMC435-TiDP16-C113: A Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics of TMC435 (clinicaltrials.gov) - Aug 15, 2012
P1, N=23, Completed, Sponsor: Tibotec Pharmaceuticals, Ireland
Active, not recruiting --> Completed N=17 --> 23
- || Olysio (simeprevir) / J&J, Medivir
Enrollment change: A Study to Assess Bioavailability & Food Effect of Different Liquid and Capsule Formulations of TMC435. (clinicaltrials.gov) - Jul 5, 2012
P1, N=72, Completed, Sponsor: Janssen R&D Ireland
N=17 --> 23 N=13 --> 72
- ||||| Daklinza (daclatasvir) / BMS
New P2 trial, Combination therapy: Study of Daclatasvir (BMS-790052) and Simeprevir (TMC435) in Patients With Genotype 1 Chronic Hepatitis C Virus (clinicaltrials.gov) - Jun 25, 2012
P2, N=180, Active, not recruiting, Sponsor: Bristol-Myers Squibb
- ||| Olysio (simeprevir) / J&J, Medivir
Trial completion: A Study to Assess Bioavailability & Food Effect of Different Liquid and Capsule Formulations of TMC435. (clinicaltrials.gov) - Jun 17, 2012
P1, N=72, Completed, Sponsor: Janssen R&D Ireland
N=13 --> 72 Recruiting --> Completed
- birinapant (IGM-9427) / IGM Biosciences
New P1 trial, Combination therapy, Metastases: Gemcitabine Hydrochloride and Smac Mimetic TL32711 in Treating Patients With Advanced Solid Tumors (clinicaltrials.gov) - Apr 8, 2012
P1, N=21, Terminated, Sponsor: Roswell Park Cancer Institute
- ||| Olysio (simeprevir) / J&J, Medivir
New P1 trial: A Study to Assess Bioavailability & Food Effect of Different Liquid and Capsule Formulations of TMC435. (clinicaltrials.gov) - Apr 3, 2012
P1, N=72, Completed, Sponsor: Janssen R&D Ireland
- |||||||||| Olysio (simeprevir) / J&J, Medivir
New P3 trial, Combination therapy: RESTORE: A Study to Evaluate the Efficacy, Safety and Tolerability of TMC435 in Combination With PegIFN Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment-Naïve or Treatment-Experienced, Chronic Hepatitis C Virus Genotype-4 Infected Patients (clinicaltrials.gov) - Mar 28, 2012
P3, N=107, Completed, Sponsor: Janssen R&D Ireland
- | Olysio (simeprevir) / J&J, Medivir
Trial completion: A Study in Healthy Female Participants Investigating the Effect of TMC435 on the Pharmacokinetics of the Synthetic Hormones of the Oral Contraceptive Ovysmen (clinicaltrials.gov) - Feb 13, 2012
P1, N=18, Completed, Sponsor: Tibotec Pharmaceuticals, Ireland
Recruiting --> Completed Active, not recruiting --> Completed
- | Olysio (simeprevir) / J&J, Medivir
Trial completion: TMC435-TiDP16-C126 - Trial to Investigate the Effect of Severe Renal Impairment on the Pharmacokinetics and Safety of TMC435 (clinicaltrials.gov) - Jan 29, 2012
P1, N=16, Completed, Sponsor: Tibotec Pharmaceuticals, Ireland
Active, not recruiting --> Completed Recruiting --> Completed
- | Olysio (simeprevir) / J&J, Medivir
Trial completion: A Study in Healthy Participants Investigating the Effect of TMC435 on the Pharmacokinetics of Immunosuppressants Cyclosporine and Tacrolimus (clinicaltrials.gov) - Jan 9, 2012
P1, N=29, Completed, Sponsor: Tibotec Pharmaceuticals, Ireland
Recruiting --> Completed Active, not recruiting --> Completed
- |||| Olysio (simeprevir) / J&J, Medivir
Trial completion: ASPIRE: A Safety and Effectiveness Study of TMC435 in Chronic, Genotype 1, Hepatitis C Patients Who Failed to Previous Standard Treatment (clinicaltrials.gov) - Jan 9, 2012
P2b, N=464, Completed, Sponsor: Tibotec Pharmaceuticals, Ireland
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||| TMC647055 / J&J, Olysio (simeprevir) / J&J, Medivir
Trial completion, Combination therapy: TMC647055HPC1001 - First-in-human Trial to Examine Safety, Tolerability and Pharmacokinetics (How the Drug is Absorbed Into the Bloodstream) of Increasing Single Oral Doses and of Increasing Repeated Oral Doses of TMC647055 in Healthy Volunteers and in Hepatitis C Virus Infected Patients (clinicaltrials.gov) - Dec 14, 2011
P1, N=72, Completed, Sponsor: Tibotec Pharmaceuticals, Ireland
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||| Olysio (simeprevir) / J&J, Medivir
Trial completion: TMC435-TiDP16-C117: The Effect of TMC435 on the Results of Electrocardiograms (Electric Recording of the Heart) in Healthy Volunteers (clinicaltrials.gov) - Dec 6, 2011
P1, N=60, Completed, Sponsor: Tibotec Pharmaceuticals, Ireland
Active, not recruiting --> Completed Active, not recruiting --> Completed